Evidence map›Paper›PMID 31223055›Full record

ArticlemAbs

Native peptide mapping - A simple method to routinely monitor higher order structure changes and relation to functional activity.

Michel Degueldre, Annemie Wielant, Eglantine Girot, Will Burkitt, John O'Hara, Gaël Debauve, Annick Gervais, Carl Jone

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Michel DegueldreDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.ORCID 0000-0002-6034-0539
Annemie WielantDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.
Eglantine GirotDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.
Will BurkittDepartment of Analytical Science Biologicals, UCB , Slough , UK.
John O'HaraDepartment of Analytical Science Biologicals, UCB , Slough , UK.
Gaël DebauveDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.ORCID 0000-0002-6720-7423
Annick GervaisDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.
Carl JoneDepartment of Analytical Science Biologicals, UCB , Braine L'Alleud , Belgium.
UCB Pharma (Belgium) · BEUCB Pharma (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the biopharmaceutical environment, controlling the Critical Quality Attributes (CQA) of a product is essential to prevent changes that affect its safety or efficacy. Physico-chemical techniques and bioassays are used to screen and monitor these CQAs. The higher order structure (HOS) is a CQA that is typically studied using techniques that are not commonly considered amenable to quality control laboratories. Here, we propose a peptide mapping-based method, named native peptide mapping, which could be considered as straightforward for HOS analysis and applicable for IgG4 and IgG1 antibodies. The method was demonstrated to be fit-for-purpose as a stability-indicating assay by showing differences at the peptide level between stressed and unstressed material. The unfolding pathway induced by a heat stress was also studied via native peptide mapping assay. Furthermore, we demonstrated the structure-activity relationship between HOS and biological activity by analyzing different types of stressed samples with a cell-based assay and the native peptide mapping. The correlation between both sets of results was highlighted by monitoring peptides located in the complementary-determining regions and the relative potency of the biotherapeutic product. This relationship represents a useful approach to interrogate the criticality of HOS as a CQA of a drug.

Indexed as

Peptide MappingAnimalsAntibodies, MonoclonalDogsHumansImmunoglobulin GMadin Darby Canine Kidney CellsAntibodies, MonoclonalImmunoglobulin GBioassayBiopharmaceuticalHigher Order Structuremass spectrometryMethod Developmentmonoclonal antibodypeptide mappingquality controlstabilitystructure activity relationship

Identifiers

PMID31223055
PMCPMC6816347
OpenAlexW2949217616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.